Influence of Malondialdehyde and Matrix Metalloproteinase-9 on Progression of Carotid Atherosclerosis in Chronic Renal Disease with Cardiometabolic Syndrome

Table 2

The serum concentration of MDA and MMP-9 in different patient subgroups according to atherosclerotic stage.

	AS0	AS1/2	AS3
CKD
MDA (ng/mL)	24.1 (18.8–27)	40.3 (31.9–45.6)	74.3 (68.2–76.3)	<0.01
MMP-9 (ng/mL)	320 (250–350)	425.2 (405.5–439.5)	462.4 (458.1–464.2)	<0.01
PD
MDA (ng/mL)	20.6 (10.4–31.3)	35.6 (28.3–39.1)	53.9 (49.8–63.2)	<0.01
MMP-9 (ng/mL)	369.4 (350.5–432.6)	374.8 (346.4–397.7)	469.3 (464–480.6)	<0.01